These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 24636548)

  • 1. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
    Peck KY; Lim YZ; Hopper I; Krum H
    Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
    Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
    Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
    Kadish A; Dyer A; Daubert JP; Quigg R; Estes NA; Anderson KP; Calkins H; Hoch D; Goldberger J; Shalaby A; Sanders WE; Schaechter A; Levine JH;
    N Engl J Med; 2004 May; 350(21):2151-8. PubMed ID: 15152060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?".
    Zecchin M; Merlo M; Pivetta A; Barbati G; Lutman C; Gregori D; Serdoz LV; Bardari S; Magnani S; Di Lenarda A; Proclemer A; Sinagra G
    Am J Cardiol; 2012 Mar; 109(5):729-35. PubMed ID: 22176998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of prophylactic implantable defibrillator therapy in patients with nonischemic cardiomyopathy: what have we learned and what can we expect from future trials?
    Grimm W
    Card Electrophysiol Rev; 2003 Dec; 7(4):463-7. PubMed ID: 15071276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H; Haas SJ; Eichhorn E; Ghali J; Gilbert E; Lechat P; Packer M; Roecker E; Verkenne P; Wedel H; Wikstrand J
    Eur Heart J; 2005 Oct; 26(20):2154-8. PubMed ID: 16014644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction.
    McAlister FA; Ezekowitz J; Dryden DM; Hooton N; Vandermeer B; Friesen C; Spooner C; Rowe BH
    Evid Rep Technol Assess (Full Rep); 2007 Jun; (152):1-199. PubMed ID: 17764218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.
    Katritsis DG; Siontis KC; Bigger JT; Kadish AH; Steinman R; Zareba W; Siontis GC; Bardy GH; Ioannidis JP
    Heart Rhythm; 2013 Feb; 10(2):200-6. PubMed ID: 23107652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Hammer-Hansen S; Voges I; Nyktari E; Raja AA; Svendsen JH; Pehrson S; Signorovitch J; Køber LV; Prasad SK; Thune JJ
    Circ Arrhythm Electrophysiol; 2019 Mar; 12(3):e007022. PubMed ID: 30866666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
    Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
    Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators.
    Santangeli P; Di Biase L; Dello Russo A; Casella M; Bartoletti S; Santarelli P; Pelargonio G; Natale A
    Ann Intern Med; 2010 Nov; 153(9):592-9. PubMed ID: 21041579
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.